

N-Phosphinyl Phosphoramidate—A Chiral Brønsted Acid Motif for the Direct Asymmetric N,O-Acetalization of Aldehydes**

Sreekumar Vellalath, Ilija Čorić, and Benjamin List*

The advent of 1,1'-binaphthalene-2,2'-diol (BINOL) phosphates as powerful Brønsted acid catalysts heralded a new era in asymmetric organocatalysis.^[1] The recognition of the bifunctional mode of activation of these catalysts in reactions of imines with nucleophiles inspired organic chemists to design a variety of new asymmetric transformations.^[2] At the same time, significant effort has also been devoted to the construction of other Brønsted acid motifs such as thioureas,^[3] dicarboxylic acids,^[4] and disulfonic acids.^[5] A remarkable innovation in this area occurred when Yamamoto et al. introduced *N*-triflyl phosphoramidates for the activation of less reactive substrates such as ketones, silyl enol ethers, and aldehydes.^[6–8] Our recent discovery of chiral disulfonimides and their use as Lewis acid precatalysts for the activation of aldehydes, has revealed yet another potentially important class of chiral acid catalysts.^[9] In research on BINOL-derived phosphoric acids little effort has been made towards the design of new analogues with alternative functionalities, except for certain modifications of their backbone^[10] and the above-mentioned derivatization. As theoretical studies confirm that these catalysts simultaneously activate electrophiles by protonation and nucleophiles through interaction with the basic P=O group,^[11] we are interested in exploring derivatives with alternative acidic and basic sites to further expand the utility of this fascinating type of organocatalyst.^[12] Here we introduce *N*-phosphinyl phosphoramidates as a new motif for organocatalysis (Figure 1).

We hypothesized that the additional basic P=O functionality of an *N*-phosphinyl phosphoramidate could stabilize different transition-state geometries in the bifunctional activation of two reacting substrates. Additionally, by bringing in two new substituents, these catalysts could be easily modified and fine-tuned for a particular reaction. We now show that this new class of Brønsted acids can indeed be used in the first highly enantioselective direct N,O-acetalization of aldehydes.

Cyclic N,O-acetals are a frequently encountered structural motif in natural products and in pharmaceuticals.^[13–14]





Figure 1. *N*-Phosphinyl phosphoramidate as a new motif for asymmetric Brønsted acid catalysis.

The importance of the stereochemistry of the acetal carbon in N,O-acetal-containing drugs is illustrated by the different bioactivities of their enantiomers.^[14a,15] In 2005, Antilla et al. reported the first catalytic asymmetric method for the synthesis of chiral aminals by the addition of sulfonamides to imines, using a VAPOL (vaulted biphenanthrol)-derived phosphoric acid.^[16] They also extended this strategy to the preparation of chiral N,O-acetals by the BINOL phosphoric acid catalyzed enantioselective addition of alcohols to *N*-benzoyl imines.^[17] However, this methodology is limited to acyclic N,O-acetals and to the use of preformed imines as electrophiles. As part of our long-standing interest in the development of asymmetric acetalization reactions,^[18] we reported the direct enantioselective synthesis of cyclic aminals from aldehydes through a sequence consisting of imine formation and intramolecular amidation (Scheme 1).^[19] However, analogous N,O-acetalizations have been entirely unknown, which is unsatisfying since cyclic N,O-acetals, especially benzoxazinones, have recently gained importance because of their pharmaceutical applications.^[20] For example, chlorothienoxazine is well appreciated for its analgesic activity.^[21] So far only achiral acids or amines have been used in the preparation of benzoxazinones from substituted



Scheme 1. Catalytic asymmetric N,N- and N,O-acetalizations.

[*] Dr. S. Vellalath, I. Čorić, Prof. Dr. B. List
Max-Planck-Institut für Kohlenforschung
Kaiser Wilhelm-Platz 1, 45470 Mülheim an der Ruhr (Germany)
Fax: (+49) 208-306-2982
E-mail: list@mpi-muelheim.mpg.de

[**] We thank the Alexander von Humboldt Foundation (fellowship for S.V.), the Max-Planck-Society, the DFG (Priority Program Organocatalysis SPP1179), and the Fonds der Chemischen Industrie for support.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201005347>.

salicylamides and aldehydes.^[22,23] Indeed, we found this transformation to be extremely challenging when we tested a variety of established chiral Brønsted acid catalysts. Consequently, we embarked on the development of a new chiral catalyst for the asymmetric synthesis of benzoxazinones from aldehydes.

In our initial studies we exposed a mixture of 2-hydroxy-4-methylbenzamide (**1a**) and isovaleraldehyde (**2a**) to a catalytic amount of (*S*)-TRIP^[24] (**4**) (10 mol %) at 50 °C (Figure 2). A slow but efficient reaction occurred and the benzoxazinone^[25] derivative **3a** was obtained with a promis-




Figure 2. Catalysts tested.

ing e.r. of 78:22 (Table 1, entry 1). The more acidic *N*-triflyl phosphoramidate catalyst **5** resulted in reduced enantioselectivity (Table 1, entry 2). As various other phosphoric acids also failed to give an improvement,^[26] we began focusing on the development of the novel bisphosphorylimide catalyst **6**, which was easily accessible from (*S*)-TRIP chloride (TRIP-Cl) and diphenyl phosphoramidate using NaH as the

base.^[26,27] Use of catalyst **6** provided product **3a** with an improved enantioselectivity of 85:15 e.r. (Table 1, entry 3). To further rigidify the chiral pocket provided by the catalyst, we explored the possibility of replacing the phenoxide moiety in **6** with other groups. In the event, several chiral *N*-phosphinyl phosphoramidates (**7a–f**) were synthesized from the corresponding diaryl phosphinamide and TRIP-Cl and were tested in the model reaction. Gratifyingly, catalyst **7a** considerably improved the enantioselectivity but at the expense of the reaction rate (Table 1, entry 4). Interestingly, the arene substituents present in the phosphinyl moiety exerted a striking influence on the reaction outcome.

While catalysts **7a** (Ar=Ph) and **7b** (Ar=4-*t*BuC₆H₄) gave similar results, aryl groups containing electron-withdrawing substituents at the *meta* positions provided higher reaction rates but gave significantly lower enantioselectivities (Table 1, entries 6 and 7). Gratifyingly, we found that catalyst **7e** with a *para*-fluorophenyl group, significantly improved the enantioselectivity, although the yield was only moderate (Table 1, entry 8). A further improvement in both the reaction rate and the enantioselectivity was observed with catalyst **7f** (Ar=4-CF₃C₆H₄; Table 1, entry 9), which provided the product **3a** with an e.r. of 95:5 and was selected for exploration of the substrate scope. The yield of the reaction could be further improved to 90% by using an excess of aldehyde (Table 1, entry 10).

With the optimized conditions in hand, we tested a variety of aldehydes in the reaction with amide **1a** (Table 2). The *N,O*-acetalization catalyzed by *N*-phosphinyl phosphoramidate **7f** proved to be quite general. Aliphatic α -unbranched and α -branched aldehydes were converted into benzoxazinones **3** with high yields and enantioselectivities (Table 2, entries 1–5). The linear aliphatic aldehyde **2g** afforded still good but slightly lower enantioselectivity (Table 2, entries 6 and 7), while benzaldehyde gave rather moderate enantioselectivity (entry 8). We further investigated the applicability of this

Table 1: Optimization of reaction conditions.

Entry ^[a]	Catalyst	Yield [%] ^[b]	e.r. ^[c]
1	4	66	78.0:22.0
2	5	74	57.0:43.0
3	6	80	85.0:15.0
4	7a	52	93.5:6.5
5	7b	50	94.0:6.0
6	7c	75	60.0:40.0
7	7d	73	87.5:12.5
8	7e	64	94.5:5.5
9	7f	73	95.0:5.0
10 ^[d]	7f	90	95.0:5.0

[a] Unless otherwise specified, reactions were performed on 0.1 mmol scale (0.05 M solution), 5 Å M.S. (50 mg). [b] Yield of isolated product. [c] Enantiomeric ratios were determined by HPLC analysis on a chiral stationary phase. [d] Reaction carried out with 8 equivalents of **2a**.

Table 2: Aldehyde scope.

Entry ^[a]	RCHO	Product	Yield [%] ^[b]	e.r. ^[c]
1	<i>i</i> BuCHO (2a)	3a	90	95.0:5.0
2	<i>t</i> BuCH ₂ CHO (2b)	3b	94	94.5:5.5
3	<i>i</i> PrCHO (2c)	3c	90	96.0:4.0
4	(Et) ₂ CHCHO (2d)	3d	81	98.0:2.0
5	CyCHO (2e)	3e	95	96.0:4.0
6	PhCH ₂ CHO (2f)	3f	83	91.5:8.5
7	<i>n</i> PrCHO (2g)	3g	97	92.0:8.0
8	PhCHO (2h)	3h	50	75.5:24.5
9 ^[d]	2i	3i	69	syn: 98.5:1.5 anti: 86.5:13.5

[a] The reactions were performed with 0.1 mmol of **1a** and 0.8 mmol of **2**, 5 Å M.S. (50 mg). [b] Yield of isolated product. [c] Enantiomeric ratios were determined by HPLC analysis on a chiral stationary phase. [d] 2-Hydroxybenzamide (**1b**) was used. Cy = cyclohexyl.

catalyst system to the diastereoselective N,O-acetalization of 2-phenyl propionaldehyde. The reaction delivered product **3i** in good yield with 1:1 d.r. (Table 2, entry 9). The *syn* product was obtained with an excellent e.r. of 98.5:1.5 and the *anti* isomer with 86.5:13.5 e.r.^[28]

The generality of the reaction was also investigated with several substituted 2-hydroxybenzamides (Table 3). The electronic properties of the arene substituents showed little influence on the enantioselectivity and all, electron-rich,


Table 3: 2-Hydroxybenzamide scope.

Entry ^[a]	X	Product	Yield [%] ^[c]	e.r. ^[d]
1	H (1b)	3j	89	95.0:5.0
2 ^[b]	3-Me (1c)	3k	96	96.0:4.0
3	5-Me (1d)	3l	97	96.0:4.0
4	6-Me (1e)	3m	97	94.0:6.0
5	4-OMe (1f)	3n	98	95.5:4.5
6	5-OMe (1g)	3o	95	94.5:5.5
7	4-Me, 5-Br (1h)	3p	91	96.0:4.0
8 ^[b]	5-Me, 3-Br (1i)	3q	84	95.0:5.0
9	4-Me, 3,5-Cl (1j)	3r	78	95.5:4.5
10	5-Cl (1k)	3s	88	95.0:5.0
11	5-F (1l)	3t	89	95.0:5.0
12	1m	3u	95	93.5:6.5

[a] The reactions were performed with 0.1 mmol of **1** and 0.8 mmol of **2b**, 5 Å M.S. (50 mg). [b] The reaction was carried out at 60°C. [c] Yield of isolated product. [d] Enantiomeric ratios were determined by HPLC analysis on a chiral stationary phase.

electron-neutral, and electron-poor benzamides furnished the corresponding products in similarly high yields and enantioselectivities. While substrate **1j**, substituted with two chlorine atoms, gave slightly lower yield, the enantioselectivity remained excellent (Table 3, entry 9). Furthermore, 3-hydroxynaphthamide (**1m**) gave the corresponding product **3u** with similarly high enantioselectivity (Table 3, entry 12). The absolute configuration of N,O-acetal **3p** was determined to be *R* by single-crystal X-ray analysis.^[28] The absolute configuration of all other products was assigned by analogy.

We were also able to demonstrate the utility of our methodology in the synthesis of the analgesic pharmaceutical chlorothoxazine (**9**, Scheme 2). The enantiomers of this drug have been separated before by chromatography on a chiral stationary phase, but the biological properties of the individual enantiomers have not yet been determined.^[29] Using standard conditions, we obtained the product in good yield with reasonable enantioselectivity (e.r. 86:14).^[30] Importantly,



Scheme 2. Synthesis of chlorothoxazine

tantly, highly enantiomerically enriched product **9** could be obtained after a single recrystallization from methanol.

Mechanistically, we believe the reaction to proceed via an *N*-benzoylimine, generated from the aldehyde and 2-hydroxybenzamide. Protonation of the imine with catalyst **7f** delivers a chiral ion pair, in which the chiral counteranion dictates the approach of the phenol nucleophile towards the *re* enantioface of the imine as shown in Figure 3. In accordance with our design, we propose that the Brønsted basic phosphinyl oxygen (²P=O) activates the nucleophile in the transition state.





Figure 3. Stereochemical model.

To obtain further evidence for the intermediacy of a benzoylimine, we prepared enamide **10** as a latent imine surrogate by means of Cu-catalyzed *N*-alkenylation and subjected it to the acetalization reaction conditions (Scheme 3). This reaction afforded the corresponding product with the same enantioselectivity as in the two-component reaction suggesting the imine as a common intermediate.



Scheme 3. Synthesis and cyclization of enamide **10**. DMEDA = *N,N'*-dimethylethylenediamine.

In conclusion, we have designed chiral *N*-phosphinyl phosphoramides as a new motif for asymmetric Brønsted acid catalysis. The *N*-phosphinyl phosphoramide **7f** was identified

as the first highly effective and enantioselective catalyst for the direct synthesis of cyclic N,O-acetals from aldehydes and hydroxy amides. The additional functional group and substituents of the *N*-phosphinyl phosphoramidate allow expeditious fine-tuning of the chiral Brønsted acid catalyst. The potentially broad utility of this motif will be further explored in our laboratories.

Received: August 26, 2010

Published online: November 9, 2010

Keywords: Brønsted acid catalysis · cyclic N,O-acetals · organocatalysis · *N*-phosphinyl phosphoramidates

- [1] a) T. Akiyama, J. Itoh, K. Yokota, K. Fuchibe, *Angew. Chem.* **2004**, *116*, 1592–1594; *Angew. Chem. Int. Ed.* **2004**, *43*, 1566–1568; b) T. Akiyama, *Chem. Rev.* **2007**, *107*, 5744–5758.
- [2] M. Terada, *Synthesis* **2010**, 1929–1982.
- [3] A. G. Doyle, E. N. Jacobsen, *Chem. Rev.* **2007**, *107*, 5713–5743.
- [4] T. Hashimoto, K. Maruoka, *J. Am. Chem. Soc.* **2007**, *129*, 10054–10055.
- [5] a) S. C. Pan, B. List, *Chem. Asian J.* **2008**, *3*, 430–437; b) D. Kampen, A. Ladépêche, G. Cläßen, B. List, *Adv. Synth. Catal.* **2008**, *350*, 962–966; c) M. Hatano, T. Maki, K. Moriyama, M. Arinobe, K. Ishihara, *J. Am. Chem. Soc.* **2008**, *130*, 16858–16860.
- [6] D. Nakashima, H. Yamamoto, *J. Am. Chem. Soc.* **2006**, *128*, 9626–9627.
- [7] C. H. Cheon, H. Yamamoto, *J. Am. Chem. Soc.* **2008**, *130*, 9246–9247.
- [8] C. H. Cheon, H. Yamamoto, *Org. Lett.* **2010**, *12*, 2476–2479.
- [9] P. García-García, F. Lay, P. García-García, C. Rabalakos, B. List, *Angew. Chem.* **2009**, *121*, 4427–4430; *Angew. Chem. Int. Ed.* **2009**, *48*, 4363–4366. Also see: a) M. Treskow, J. Neudörfl, R. Giernoth, *Eur. J. Org. Chem.* **2009**, 3693–3697; b) H. He, L.-Y. Chen, W.-Y. Wong, W.-H. Chan, A. W. M. Lee, *Eur. J. Org. Chem.* **2010**, 4181–4184.
- [10] a) X. Cheng, R. Goddard, G. Buth, B. List, *Angew. Chem.* **2008**, *120*, 5157–5159; *Angew. Chem. Int. Ed.* **2008**, *47*, 5079–5081; b) X.-H. Chen, W.-Q. Zhang, L.-Z. Gong, *J. Am. Chem. Soc.* **2008**, *130*, 5652–5653.
- [11] a) M. Yamanaka, J. Itoh, K. Fuchibe, T. Akiyama, *J. Am. Chem. Soc.* **2007**, *129*, 6756–6764; b) L. Simon, J. L. Goodman, *J. Am. Chem. Soc.* **2009**, *131*, 4070–4077.
- [12] V. N. Wakchaure, B. List, *Angew. Chem.* **2010**, *122*, 4230–4243; *Angew. Chem. Int. Ed.* **2010**, *49*, 4136–4139.
- [13] a) L. Heys, C. G. Moore, P. J. Murphy, *Chem. Soc. Rev.* **2000**, *29*, 57–67; b) P. Langer, J. Frackenpohl, H. M. R. Hoffmann, *J. Chem. Soc. Perkin Trans. 1* **1998**, 801–806.
- [14] For a Lewis acid catalyzed enantioselective synthesis of oxazopyrazinone, see a) F. Saitoh, H. Nishida, T. Mukaihira, K. Aikawa, K. Mikami, *Eur. J. Org. Chem.* **2006**, 2269–2272; b) for 3,4-benzo-5-oxacephams, see: A. Kozioł, J. Frelek, M. Woźnica, B. Furman, M. Chmielewski, *Eur. J. Org. Chem.* **2009**, 338–341.
- [15] D. P. Uzunov, I. Zivkovich, W. H. Pirkle, E. Costa, A. Guidotti, *J. Pharm. Sci.* **1995**, *84*, 937–942.
- [16] a) G. B. Rowland, H. Zhang, E. B. Rowland, S. Chennamadhavuni, Y. Wang, J. C. Antilla, *J. Am. Chem. Soc.* **2005**, *127*, 15696–15697; b) Y. Liang, E. B. Rowland, G. B. Rowland, J. A. Perman, J. C. Antilla, *Chem. Commun.* **2007**, 4477–4479.
- [17] G. Li, F. R. Fronczek, J. C. Antilla, *J. Am. Chem. Soc.* **2008**, *130*, 12216–12217.
- [18] Also see: I. Čorić, S. Vellalath, B. List, *J. Am. Chem. Soc.* **2010**, *132*, 8536–8537.
- [19] a) X. Cheng, S. Vellalath, R. Goddard, B. List, *J. Am. Chem. Soc.* **2008**, *130*, 15786–15787; b) For an independent report, see: M. Rueping, A. P. Antonchick, E. Sugiono, K. Grenader, *Angew. Chem.* **2009**, *121*, 925–927; *Angew. Chem. Int. Ed.* **2009**, *48*, 908–910.
- [20] a) E. Chiang, J. Finkelstein, *J. Med. Chem.* **1968**, *11*, 1038–1040; b) G. R. Madhavan, R. Chakrabarti, K. A. Reddy, B. M. Rajesh, V. Balraju, P. B. Rao, R. Rajagopalan, J. Iqbal, *Bioorg. Med. Chem.* **2006**, *14*, 584–591.
- [21] R. Kadatz, *Arzneim.-Forsch.* **1957**, *7*, 651.
- [22] a) C. A. Keane, W. W. S. Nicholls, *J. Chem. Soc.* **1907**, *91*, 266; b) A. W. Tilherley, *J. Chem. Soc.* **1907**, *91*, 1425; c) W. L. Hicks, *J. Chem. Soc.* **1910**, *97*, 1368; d) B. W. Horrom, H. E. Zugg, *J. Am. Chem. Soc.* **1950**, *72*, 721.
- [23] R. B. Gammill, *J. Org. Chem.* **1981**, *46*, 3340–3342.
- [24] G. Adair, S. Mukherjee, B. List, *Aldrichimica Acta* **2008**, *41*, 31–39.
- [25] Benzoxazinone derivatives are configurationally stable under the reaction conditions but undergo racemization in the presence of strong acids such as pTSA (see the Supporting Information).
- [26] See the Supporting Information for details.
- [27] For the use of [(PhO)₂PO]₂NH as a catalyst, see: C. A. Bruynes, T. K. Jurriens, *J. Org. Chem.* **1982**, *47*, 3966–3969.
- [28] CCDC 783003 (racemic *syn*-**3i**) and CCDC 782129 (**3p**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- [29] J. Dönnecke, W. A. König, O. Gyllenhaal, J. Vessman, C. Schulze, *J. High Resolut. Chromatogr.* **1994**, *17*, 779–783.
- [30] The low e.r. in the reaction may be a consequence of the generation of trace amount of HCl from the decomposition of β-chloropropionaldehyde.